A b s t r a c t BACKGROUND: With disease-modifying drugs on the horizon for degenerative ataxias,
RESULTS: A set of gait variability measures was identified which allowed to consistently identify ataxic gait changes in all three conditions. Lateral step deviation and a compound measure of step length categorized patients against controls in real life with a discrimination accuracy of 0.86. Both were highly correlated with clinical ataxia severity (effect size ρ =0.76). These measures allowed detecting group differences even for patients who differed only 1 point in the SARA p&g subscore, with highest effect sizes for real-life walking (d=0.67).
CONCLUSIONS:
We identified measures of ataxic gait that allowed not only to capture the gait variability inherent in ataxic gait in real life, but also demonstrate high sensitivity to small differences in disease severity -with highest effect sizes in real-life walking. They thus represent promising candidates for quantitative motor markers for natural history and treatment trials in ecologically valid contexts.
Gait disturbances often present as the first signs of degenerative cerebellar ataxia (DCA) 1, 2 and are one of the most disabling features throughout the disease course. It has been shown in laboratory-based assessments that measures of spatial and temporal movement variability allow distinctively to capture and characterize the specificities of ataxic gait [3] [4] [5] [6] [7] [8] [9] [10] . Moreover, they allow to quantify disease severity even at preclinical stages of DCA 11, 12 and to capture treatment-induced improvements in a fine-grained fashion [13] [14] [15] , thus suggesting a high potential as both progression and treatment response parameters in the upcoming treatment trials [16] [17] [18] . Recently, first studies showed that such measures of spatio-temporal variability characterizing ataxic gait can also be captured using wearable inertial sensors in clinical assessments 19, 20 . With their easy handling outside from specialized gait laboratories, these systems are particularly promising for conduction of multi-centered studies. Moreover, driven by advances in sensor technologies, wearable sensors increasingly enable remote capturing of patients' movements in their real life. This might allow to capture patients' real-world motor performance and ecologically meaningful intervention-induced improvements, rather than "snapshot" performance during constrained and partly "artificial" surrogate motor tasks assessed by clinical scores or lab conditions 21 .
While wearable sensors have already proven their value to capture and quantify characteristics of real-life movement in neurological diseases like Parkinson's disease 22, 23 or multiple sclerosis 24 , studies are still lacking which capture the specifics of ataxic gait in real life beyond the level of mere physical activity [25] [26] [27] .
The transfer of spatio-temporal variability measures for quantifying ataxic gait impairments into real life is hereby complicated by the fact that real life gait is in general inherently far more variable for both healthy controls and cerebellar patients 28 and that patients are free to use various compensation strategies, thus increasing heterogeneity of walking patterns and complexity of gait scenarios. Thus, spatio-temporal gait measures may lose their accuracy for characterizing ataxic gait changes in real life.
Here we aimed to unravel spatio-temporal gait measures in real-life environments that allow to quantify not just unspecific walking changes in ataxia (e.g. decreased walking speed), but features inherent to ataxic gait changes in DCA-as it will be these features that will be particularly sensitive to change by upcoming treatment trials specifically targeting cerebellar Out of the respective total groups, 21 CA patients and 17 HC were available for the RLW condition (for an overview of these subjects, see Table 1 ). Step events, as well as spatio-temporal gait parameters from the IMU sensors were extracted using APDM's mobility lab software (Version 2) 31 , which has been shown to deliver good-to-excellent accuracy and repeatability 32, 33 . For each detected stride, the following features were extracted: stride length, stride time, lateral step deviation and raw accelerometer data of the lumbar sensor. Variability measures were calculated using the coefficient of variation CV=σ/μ, normalizing the standard deviation with the mean value 34 . On this basis, stride length CV (StrideL CV ) and stride time CV (StrideT CV ) were determined, which have shown to be sensitive to ataxia severity in constrained lab-based walking 3, 5, 7, 11, 12 .
The measure of lateral step deviation (LatStepDev) was determined on the basis of three consecutive walking steps, calculating the perpendicular deviation of the middle foot placement from the line connecting the first and the third step (see Supplement S1, Figure 1 ).
LatStepDev was normalized with stride length (% of stride length), thus providing a measure independent from step length variability, which is suggested to be increased in real-life gait.
In order to establish a measure which captures different types of spatial step variability, we combined the measure of step length variability (StrideL CV ) (mostly anterior-posterior direction) with the measure of lateral step deviation (LatStepDev) (medio-lateral dimension).
The spatial step variability compound measure SPcmp determines for each of the two parameters (StrideL CV ) and (LatStepDev) the relative value of an individual subject in comparison to the value range of all subjects (resulting in values between [0-1]) and takes the maximum of both values (see also Figure 2 in Supplement S1).
In addition, harmonic ratio (HR) 35 
the HR quantifies the harmonic composition of these accelerations for a given stride where a higher HR is interpreted as greater walking smoothness (see Supplement S1 for a more formal description).
It has been recently shown that HR measures distinguish between cerebellar patients and healthy controls in lab-based walking trails 20 [3] [4] ; severe CA Sev :=SARA g&p [5] [6] .
Receiver operating characteristic (ROC) analysis determining the classification accuracy was used to quantify the discrimination capability of the examined measures for different walking conditions.
Repeated measurements analyses were performed using the non-parametric Friedman test (χ 2 ,p-values) to determine within-group differences between walking conditions. When the Friedman test yielded a significant effect (p<0.05), post hoc analysis was performed using a
Wilcoxon signed-rank test for pairwise comparisons between assessments. We report three significance levels: (i) uncorrected *:p<0.05, (ii) Bonferroni-corrected for multiple comparisons **: p<0.05/n=7: number of analysed features, (iii) ***p<0.001.
Spearman's ρ was used to examine the correlation between movement measures and SARA scores as well as between measures for different walking conditions. Effect sizes were classified as ρ : 0.1 small effect, 0.3 medium effect, 0.5 large effect, 0.7 very large effect 38, 39 .
To analyse the sensitivity of the movement measures to detect clinically important changes in ataxia severity, we compared gait measures for patients with (i) a difference of 1 point as well as (ii) with a difference of 2 points in the SARA p&g subscore. These ranges are motivated by previous analysis on the responsiveness of the SARA, showing that a change of 1 SARA point can be considered as a clinically important progression 40 . In addition, they are motivated by motor intervention studies demonstrating that current treatment interventions can yield an average improvement of 1.5-2 points on the SARA p&g subscore, and that these effects represent patient-relevant improvements 14, 15, 41, 42 StrideT CV (p=0.02, d =0.86, ROC accuracy 0.72) allowed to distinguish between HC and CA (see Figure 1 and Supplement S2, Table 2 ). Effect sizes and discrimination performance were smaller than in LBW, as variability in gait measures was generally higher in these unconstrained walking conditions, which was observed in both healthy controls and patients.
In contrast, the measures LatStepDev and SPcmp showed a similarly high effect size for both unconstrained conditions (SFW, RLW) as in the constrained condition LBW, which was observed in both patients and controls (Figure 1 , see blue and red stars for differences between conditions). These measures also showed the clearest discrimination between CA All measures of spatial and temporal variability as well as the harmonic ratios were highly correlated across all three conditions in cerebellar patients (Supplement S2 Table 5 ). In contrast, only few correlations were found across conditions in healthy controls (Supplement S2 Table 6 ). Similarly, also close relationships across measures were observed for cerebellar patients, with strong correlations between harmonic ratios determining movement smoothness and spatio-temporal step variability for all walking conditions (Supplement S2, Table 7 ).
They were more pronounced in cerebellar patients than in healthy controls (Supplement S2, We observed an increased within-group spatio-temporal variability of the measures StrideL CV and StrideT CV in both healthy controls and cerebellar patients in real-world walking (condition RLW) compared to supervised constrained walking in a clinical setting (condition LBW) ( Figure 1 ). This observation, which is consistent with previous work confined to healthy subjects so far 28 The measures LatStepDev and SPcmp as well as harmonic ratios AP and V did not only allow to distinguish cerebellar patients from healthy controls in real life; they were also highly correlated to clinical ataxia severity in this condition (see Table 2 ). While harmonic ratios, StrideL CV , and StrideT CV failed to reach significance for differentiating the three severity subgroups of cerebellar patients for the real-life condition RLW, LatStepDev and SPcmp were sensitive to distinguish these severity subgroups also during real-life walking (Figure 2 ). The compound measure SPcmp hereby seems to benefit from capturing different compensation strategies used in diverse stages of disease, and might allow to capture gait ataxia in particular in more advanced disease stages (for a more detailed description on the characteristics of the measure SPcmp, see Supplement S1 Figure 3 Despite the general increase of variability in real-life walking, we observed high correlations between the constrained lab-based (LBW) and the unconstrained (SFW, RLW) walking conditions. This suggests that also the lab-based assessment might be exploited to deliver first surrogate snapshots of patients' unconstrained gait performance. However, as noted above, at least some of the measures seemed to yield larger effect sizes in real-life walking.
Moreover, our current analysis of real-life walking behaviour was limited to walking bouts of minimal five subsequent strides (rather than analysis of more complex everyday-living walking behaviours) which might explain the good correlations with the constrained walking conditions. However, real life includes a much larger variety of walking movements, for instance turning movements or initiation and termination of gait, all known to be demanding for dynamic balance control and impaired in cerebellar disease. To include these movements in future analysis of real-life walking is highly warranted to capture ecological validity in even more depth. 29 . The SARA subscore posture&gait is defined by the first three items of the SARA score which capture gait, standing and sitting 30 . #Strides denotes the number of steps analysed for the given walking condition. SAOA: sporadic adult onset ataxia; ADCA: autosomal dominant ataxia of still undefined genetic cause; EOA: early-onset ataxia of still undefined genetic cause. SCA: autosomal-dominant spinocerebellar ataxia of defined genetic type. The following diagnosis denote the gene underlying the respective ataxia type: ATM (=Ataxia teleangiectasia), SPG7 (=hereditary spastic paraplegia type 7), SYNE1 (= Autosomal recessive cerebellar ataxia type I), SETX (= AOA2: Ataxia with oculomotor apraxia type 2), ADCK3 (=ARCA 2, Autosomal-recessive cerebellar ataxia type 2); PNPLA6, ANO10 (=SCAR 10, Autosomal-recessive spinocerebellar ataxia type 10). F i g u r e s Figure 1 Shown are between-group differences between cerebellar patients (CA, orange) and healthy controls (HC, blue) within each of the different walking conditions. Shown are group differences for constrained lab-based walking (LBW), supervised free walking (SFW) and real life walking (RLW). Black stars indicate significant differences between groups (*≡ p<0.05, **≡ p<0.007 Bonferroni-corrected, ***≡ p<0.001). Shown are also within-group differences between the different walking conditions (orange stars: significant differences between walking conditions in the CA cohort; blue stars: significant differences between walking conditions in HC). Supplement S1 -Details of gait conditions and measures Walking conditions Table 1 Description of walking conditions
Condition Acronym Description
Lab-based Walking LBW Subjects walked 50m straight on a 25m indoor floor (i.e. including one turn) at their preferred speed on a pre-specified straight route in an institutional setting supervised without any distractions Supervised Free walking
SFW
Subjects walked in public indoor and outdoor spaces on an institutional compound for 5 minutes at their preferred speed without pre-specified route, but supervised by a study assessor
Real-Life Walking RLW Subjects walked as part of their individual routine of daily living in their usual indoor and outdoor settings for 4-6 hours, without pre-specified routes or supervision
Lateral Step Deviation
The measure of lateral step deviation (LatStepDev) was determined on the basis of three consecutive walking steps, calculating the perpendicular deviation of the middle foot placement from the line connecting the first and the third step (see Figure 1 ). 
Harmonic Ratios
Harmonic ratio (HR) 35 Thus, the HR quantifies the harmonic composition of these accelerations for a given stride, where a higher HR is interpreted as greater walking smoothness. 
Supplement S2 -Results

